Development of novel drug delivery system (DDS) technologies for proteomic-based drug development.

With the success of human genome projects, the focus of life science research has shifted to the functional and structural analyses of proteins, such as disease proteomics. These structural and functional analyses of expressed proteins in the cells and/or tissues are expected to contribute to the identification of therapeutically applicable proteins for various diseases. Thus, pharmaco-proteomic based drug development for protein therapies is most noticed currently. However, there is a clinical difficulty to use almost bioactive proteins, because of their very low stability and pleiotropic actions in vivo. To promote pharmaco-proteomic based drug development for protein therapies to various diseases, we have attempted to establish a system for creating functional mutant proteins (muteins) with desired properties, and to develop a site-specific polymer-conjugation system for further improving the therapeutic potency of proteins. In this review, we are introducing our original protein-drug innovation systems mentioned above.

[1]  Andreas Jeromin,et al.  Retraction: Fluorobodies combine GFP fluorescence with the binding characteristics of antibodies , 2003, Nature Biotechnology.

[2]  Yuti Chernajovsky,et al.  Targeting cytokines to inflammation sites , 2003, Nature Biotechnology.

[3]  M. Graham.  Pegaspargase: a review of clinical studies. , 2003, Advanced drug delivery reviews.

[4]  Gary Walsh.  Biopharmaceutical benchmarks—2003 , 2003, Nature Biotechnology.

[5]  Yasuo Yoshioka,et al.  Site-specific PEGylation of a lysine-deficient TNF-α with full bioactivity , 2003, Nature Biotechnology.

[6]  Y. Yoshioka,et al.  Synthesis of a poly(vinylpyrrolidone-co-dimethyl maleic anhydride) co-polymer and its application for renal drug targeting , 2003, Nature Biotechnology.

[7]  D. Wyss,et al.  Structure, biology, and therapeutic implications of pegylated interferon alpha-2b. , 2002, Current pharmaceutical design.

[8]  D. Lauffenburger,et al.  Rational cytokine design for increased lifetime and enhanced potency using pH-activated “histidine switching” , 2002, Nature Biotechnology.

[9]  D. Wyss,et al.  Structural and biological characterization of pegylated recombinant interferon alpha-2b and its therapeutic implications. , 2002, Advanced drug delivery reviews.

[10]  A. P. Chapman,et al.  PEGylated antibodies and antibody fragments for improved therapy: a review. , 2002, Advanced drug delivery reviews.

[11]  Wadih Arap,et al.  In vivo phage display and vascular heterogeneity: implications for targeted medicine. , 2002, Current opinion in chemical biology.

[12]  Y. Tsutsumi,et al.  Molecular design of bioconjugated cell adhesion peptide with a water-soluble polymeric modifier for enhancement of antimetastatic effect. , 2002, Current drug targets.

[13]  Tsuyoshi Fujiwara,et al.  An unnatural base pair for incorporating amino acid analogs into proteins , 2002, Nature Biotechnology.

[14]  W. Wilson,et al.  Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia. , 2001, The New England journal of medicine.

[15]  James J. Vincent,et al.  Lowering the isoelectric point of the Fv portion of recombinant immunotoxins leads to decreased nonspecific animal toxicity without affecting antitumor activity. , 2001, Cancer research.

[16]  Steven A. Rosenberg,et al.  Progress in human tumour immunology and immunotherapy , 2001, Nature.

[17]  J. M. Harris,et al.  Improvements in protein PEGylation: pegylated interferons for treatment of hepatitis C. , 2001, Journal of controlled release : official journal of the Controlled Release Society.

[18]  F. Veronese.  Peptide and protein PEGylation: a review of problems and solutions. , 2001, Biomaterials.

[19]  Zhi-xin Xu,et al.  Rational design of a potent, long-lasting form of interferon: a 40 kDa branched polyethylene glycol-conjugated interferon alpha-2a for the treatment of hepatitis C. , 2001, Bioconjugate chemistry.

[20]  I. Chaiken,et al.  Multisite mutagenesis of interleukin 5 differentiates sites for receptor recognition and receptor activation. , 2000, Biochemistry.

[21]  Y. Tsutsumi,et al.  Antitumor Activity of Tumor Necrosis Factor-α Conjugated with Polyvinylpyrrolidone on Solid Tumors in Mice , 2000 .

[22]  H R Hoogenboom,et al.  Natural and designer binding sites made by phage display technology. , 2000, Immunology today.

[23]  I. Pastan,et al.  Site-specific chemical modification with polyethylene glycol of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) improves antitumor activity and reduces animal toxicity and immunogenicity. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[24]  S. Nagata,et al.  Steering anti-cancer drugs away from the TRAIL , 2000, Nature Medicine.

[25]  Ira Pastan,et al.  Immunotoxins in cancer therapy. , 1999, Current opinion in investigational drugs.

[26]  W. Stemmer,et al.  Evolution of a cytokine using DNA family shuffling , 1999, Nature Biotechnology.

[27]  I. Pastan,et al.  Improving antibody affinity by mimicking somatic hypermutation in vitro , 1999, Nature Biotechnology.

[28]  P. Shaw,et al.  Site-directed polyethylene glycol modification of trichosanthin: effects on its biological activities, pharmacokinetics, and antigenicity. , 1999, Life sciences.

[29]  J. Coresh,et al.  Serum creatinine levels in the US population: third National Health and Nutrition Examination Survey. , 1998, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[30]  E. Ruoslahti,et al.  Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. , 1998, Science.

[31]  W. Murphy,et al.  Prospects for cytokine and chemokine biotherapy. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[32]  W. Ruf,et al.  Identification of surface residues mediating tissue factor binding and catalytic function of the serine protease factor VIIa. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[33]  Y. Tsutsumi,et al.  Molecular design of hybrid tumour necrosis factor-alpha. II: The molecular size of polyethylene glycol-modified tumour necrosis factor-alpha affects its anti-tumour potency. , 1996, British Journal of Cancer.

[34]  J. Nemunaitis,et al.  A phase I trial of recombinant human interleukin-6 in patients with myelodysplastic syndromes and thrombocytopenia. , 1995, Blood.

[35]  Y. Tsutsumi,et al.  Molecular design of hybrid tumour necrosis factor alpha with polyethylene glycol increases its anti-tumour potency. , 1995, British Journal of Cancer.

[36]  W. Stemmer.  Rapid evolution of a protein in vitro by DNA shuffling , 1994, Nature.

[37]  N L Burnham,et al.  Polymers for delivering peptides and proteins. , 1994, American journal of hospital pharmacy.

[38]  D. Banner,et al.  Human tumor necrosis factor alpha (TNF alpha) mutants with exclusive specificity for the 55-kDa or 75-kDa TNF receptors. , 1993, The Journal of biological chemistry.

[39]  C A Smith,et al.  Soluble tumor necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF carriers and TNF antagonists. , 1993, Journal of immunology.

[40]  T. Prangé,et al.  Localization of the active site of human tumour necrosis factor (hTNF) by mutational analysis. , 1991, The EMBO journal.

[41]  M. Yamada,et al.  Mutational analysis of structure--activity relationships in human tumor necrosis factor-alpha. , 1990, Protein engineering.

[42]  Kendall A. Smith,et al.  Interleukin 2 receptor‐targeted cytotoxicity. Receptor binding requirements for entry of a diphtheria toxin‐related interleukin 2 fusion protein into cells , 1990, European journal of immunology.

[43]  E. Borden,et al.  Lymphokines and cytokines as cancer treatment.Immunotherapy realized , 1990, Cancer.

[44]  W. M. Linehan,et al.  A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. , 1987, The New England journal of medicine.

[45]  G. P. Smith,et al.  Filamentous fusion phage: novel expression vectors that display cloned antigens on the virion surface. , 1985, Science.

[46]  F. Davis,et al.  Alteration of immunological properties of bovine serum albumin by covalent attachment of polyethylene glycol. , 1977, The Journal of biological chemistry.

[47]  Takashi,et al.  Antitumor Activity of Tumor Necrosis Factor a Conjugated with Divinyl Ether and Maleic Anhydride Copolymer on Solid Tumors in Mice' , 2006 .

[48]  T. Taguchi,et al.  Phase I study of recombinant human tumor necrosis factor , 2004, Cancer Chemotherapy and Pharmacology.

[49]  S. Ha,et al.  Poster Session 4 : Immunology ; Engineering N-glycosylation mutations in IL-12 enhances sustained cytotoxic T Lymphocyte responses for DNA immunization , 2003 .

[50]  J. M. Harris,et al.  Pegylation: a novel process for modifying pharmacokinetics. , 2001, Clinical pharmacokinetics.

[51]  Daniele Sblattero,et al.  Exploiting recombination in single bacteria to make large phage antibody libraries , 2000, Nature Biotechnology.

[52]  Y. Tsutsumi,et al.  PEGylation of lnterleukin-6 Effectively Increases Its Thrombopoietic Potency , 1997, Thrombosis and Haemostasis.